However this rate still came in below the growth rate of the US stock market as a whole. Today, I will analyse the industry outlook, as well as evaluate whether Celldex Therapeutics is lagging or leading in the industry. See our latest analysis …
The decrease was primarily driven by first quarter cash used in operating activities of approximately $28.0 million and partially offset by the receipt of $11.7 million from sales of common stock under our Cantor agreement. At March 31, …
Dr. Tibor Keler, Ph.D., serves as Executive Vice President and Chief Scientific Officer of Celldex Therapeutics Inc. since July 30, 2014. Since, May 2003, Dr. Keler has held a number of positions with Celldex, including a founder, Senior Vice …
Although Celldex used $28 million to fund operations, it generated $11.7 million in cash through sales of stock through its existing Cantor Fitzgerald agreement. You might see Celldex's net loss, though, and wonder how Celldex's cash …
March has been a good month so far for Celldex Therapeutics (NASDAQ: CLDX) shareholders. The stock is up more than 20% this month, including a big jump last week that stemmed primarily from investor anticipation of the release of …